Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Irinotecan in Relapsed/Refractory SCLC
NCT04543916Phase 2Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Jun 2021
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of venetoclax in small cell lung cancer (SCLC) (6 arms), sponsored by Virginia Commonwealth University. Primary endpoints: Recommended Phase 2 Dose at 90 Days and Efficacy of Venetoclax with Irinotecan at 180 Days. Planned start Jun 2021; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04543916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543916.